TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25889594

Group type: EXPERIMENTAL
Intervention: Quiet breathing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eucapnic hyperventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypocapnic hyperventilation
Number of subjects: 10
Study: 25890251

Group type: EXPERIMENTAL
Intervention: Intravitreal use of bone marrow-derived stem cells
Number of subjects: 20
Study: 25890322

Group type: EXPERIMENTAL
Intervention: Nutritional screening by nutritional specialists
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low lean body mass
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Few (≤3) active co-morbidities
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Compliance with nutritional supplements
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Supplementation of malnourished patients as assessed by nutritional specialists
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low weight loss
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low hemoglobin concentration
Number of subjects: 140
Study: 25890582

Group type: EXPERIMENTAL
Intervention: Intact fibrous cap (IFC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ruptured fibrous cap (RFC)
Number of subjects: 140
Study: 25890604

Group type: EXPERIMENTAL
Intervention: 12-week weight loss intervention including healthy diet information, exercise increase, and telephone-based coaching using SMART goals
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 12-week weight loss intervention
Number of subjects: 13
Study: 25890676

Group type: EXPERIMENTAL
Intervention: Weight loss group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Weight gain group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 25890798

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: 10% or greater decline in forced vital capacity (FVC)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Respiratory events leading to hospital admission
Number of subjects: 517
Study: 25891040

Group type: EXPERIMENTAL
Intervention: Sweet foods
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Savory foods
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Salty foods
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Motivation to eat (factor analysis)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Liking ratings
Number of subjects: 198
Study: 25891174

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg or 10 mg per kg every 3 weeks or 10 mg per kg every 2 weeks)
Number of subjects: 495
Study: 25891346

Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 131
Study: 25891993

Group type: EXPERIMENTAL
Intervention: C-FLAG (fludarabine and cytarabine as a 24-hr continuous infusion without idarubicin)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CI-FLAG2 (C-FLAG with idarubicin)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: C-FLAG
Number of subjects: 33
Study: 25892292

Group type: EXPERIMENTAL
Intervention: Serum magnesium (se Mg) deficiency group
Number of subjects: 143

Group type: COMPARATOR
Intervention: Serum vitamin D (se vitD) and serum calcium (se Ca)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Serum magnesium (se Mg)
Number of subjects: 143
Study: 25893247

Group type: EXPERIMENTAL
Intervention: Troponin testing capability in hospitals
Number of subjects: 14370

Group type: EXPERIMENTAL
Intervention: Use of troponin assay
Number of subjects: 14370

Group type: EXPERIMENTAL
Intervention: Biomarker testing capability
Number of subjects: 14370

Group type: EXPERIMENTAL
Intervention: Troponin testing
Number of subjects: 14370

Group type: EXPERIMENTAL
Intervention: Biomarker measurement
Number of subjects: 14370
Study: 25893603

Group type: EXPERIMENTAL
Intervention: Chromosomal microarrays to detect genomic imbalances in children with CKD
Number of subjects: 419

Group type: COMPARATOR
Intervention: Chromosomal microarrays
Number of subjects: 419
Study: 25894585

Group type: EXPERIMENTAL
Intervention: Serum copeptin levels in children with febrile seizures
Number of subjects: 161

Group type: COMPARATOR
Intervention: Serum copeptin levels in febrile controls
Number of subjects: 161

Group type: COMPARATOR
Intervention: Serum copeptin levels in children with epileptic seizures
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of copeptin
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of copeptin at different time intervals
Number of subjects: 161
Study: 25894712

Group type: EXPERIMENTAL
Intervention: Mullen Scales of Early Learning (MSEL)
Number of subjects: 399
Study: 25895428

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks
Number of subjects: 79
Study: 25895616

Group type: EXPERIMENTAL
Intervention: Cediranib 30mg oral daily (od)
Number of subjects: 74
Study: 25896080

Group type: EXPERIMENTAL
Intervention: Competitive sport
Number of subjects: 108

Group type: COMPARATOR
Intervention: Recreational sport
Number of subjects: 108
Study: 25896390

Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 9
Study: 25896421

Group type: EXPERIMENTAL
Intervention: CTC-DropMount technique following CellSearch isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC-DropMount technique
Number of subjects: 0
Study: 25896707

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 32
Study: 25896785

Group type: EXPERIMENTAL
Intervention: Work-focused rehabilitation
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 413
Study: 25896788

Group type: EXPERIMENTAL
Intervention: 8 hours MPHD with a dialysate volume of 50% of estimated body water volume
Number of subjects: 9

Group type: COMPARATOR
Intervention: 4 hours SHD using a dialysate flow of 500 mL/min
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Efficiency calculated as solute removal/litre of dialysate used
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 6 times/week 8 hours MPHD
Number of subjects: 9
Study: 25897014

Group type: EXPERIMENTAL
Intervention: PD-L1 expression by immune cells
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: PD-L1 expression by tumour cells
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: PD-L1 expression in basal-like tumours (IntClust 10)
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: PD-L1 expression in basal-like tumours (surrogate IHC-based classifier)
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: CD274 (PD-L1) amplification
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: Correlation of PD-L1 expression with T cell infiltration
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: PD-L1 expression and disease-specific survival in ER-negative disease
Number of subjects: 3916
Study: 25897792

Group type: EXPERIMENTAL
Intervention: Lomitapide (5 mg to 60 mg a day, maximum)
Number of subjects: 29
Study: 25898341

Group type: EXPERIMENTAL
Intervention: Acceptance-based Separated Family Treatment (ASFT)
Number of subjects: 0
Study: 25898394

Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire (IPAQ)
Number of subjects: 211

Group type: COMPARATOR
Intervention: SenseWear Armband (SWA)
Number of subjects: 211
Study: 25898693

Group type: EXPERIMENTAL
Intervention: Dermatophagoides mix (300, 600, 3000, 6000, and 15000 SQ+) administered at weekly intervals with 1 maintenance injection (15000 SQ+) 2 weeks after the last updosing injection.
Number of subjects: 102
Study: 25899176

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination (BFC)
Number of subjects: 3697

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol combination (FSC)
Number of subjects: 3697

Group type: EXPERIMENTAL
Intervention: BFC
Number of subjects: 3697

Group type: COMPARATOR
Intervention: FSC
Number of subjects: 3697
Study: 25899239

Group type: EXPERIMENTAL
Intervention: Fabry disease (FD) patients with MRI findings
Number of subjects: 3203

Group type: COMPARATOR
Intervention: Non-FD patients with MRI findings
Number of subjects: 3203
Study: 25899478

Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 71
Study: 25899782

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine (escalating doses of fludarabine: 15, 45, and 75 mg/m(2))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine
Number of subjects: 12
Study: 25900065

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab 1600 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (all doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous rituximab 500 mg/m²
Number of subjects: 55
Study: 25900182

Group type: EXPERIMENTAL
Intervention: Cixutumumab (10 mg/kg i.v.), Everolimus (10 mg p.o. daily), Octreotide LAR (20 mg i.m. every 21 days)
Number of subjects: 19
Study: 25900187

Group type: EXPERIMENTAL
Intervention: Prospective data recording
Number of subjects: 573
Study: 25900275

Group type: EXPERIMENTAL
Intervention: APO-E4 carriers
Number of subjects: 41

Group type: COMPARATOR
Intervention: Noncarriers
Number of subjects: 41
Study: 25900467

Group type: EXPERIMENTAL
Intervention: Agitation group (defined by SAS score of 5-7 or RASS score of +2 to +4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-agitation group (defined by SAS score below 5 or RASS score below +2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up for 72 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of sedatives and analgesics
Number of subjects: 0
Study: 25900904

Group type: EXPERIMENTAL
Intervention: RelAte intervention (shared mealtimes with a trained peer volunteer once weekly for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 100
Study: 25901047

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 747

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Baseline BDI-II score
Number of subjects: 747
Study: 25901095

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam given 30 min before a clamp during euglycemia
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam given 30 min before a clamp during hypoglycemia
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam during euglycemia
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no alprazolam)
Number of subjects: 31
Study: 25901286

Group type: EXPERIMENTAL
Intervention: AGS-003 in combination with sunitinib
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: AGS-003
Number of subjects: 21
Study: 25901550

Group type: EXPERIMENTAL
Intervention: Life-sustaining treatments (mechanical ventilation, vasopressors, renal replacement therapy)
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: ICU stay
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Time from ICU admission to death
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, vasopressors, or dialysis
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Frailty or advance directives
Number of subjects: 1671
Study: 25902042

Group type: EXPERIMENTAL
Intervention: Autologous melanocyte transplantation on amniotic membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25902322

Group type: EXPERIMENTAL
Intervention: Rocuronium (used in 99% of cases) with neostigmine for reversal (73.9% at TE, 72.0% at PACU)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Neostigmine (used for reversal of NMB)
Number of subjects: 302
Study: 25902709

Group type: EXPERIMENTAL
Intervention: Exploratory analysis from the APPLE trial assessing associations between AVN and demographics, SLE disease activity, and vitamin D deficiency.
Number of subjects: 0
Study: 25902826

Group type: COMPARATOR
Intervention: Snorers (AHI < 5)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Severe SDB cases (AHI > 30)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: AHI and hypoxemia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Body mass index and male gender
Number of subjects: 405
Study: 25902842

Group type: EXPERIMENTAL
Intervention: idursulfase 0.5 mg/kg weekly for one year
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: idursulfase
Number of subjects: 28
Study: 25902855

Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25902926

Group type: EXPERIMENTAL
Intervention: Isavuconazonium (Cresemba®)
Number of subjects: 0
Study: 25903311

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 25
Study: 25903529

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study: 25903659

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 510
Study: 25903963

Group type: EXPERIMENTAL
Intervention: PEI regimen (Cisplatin 20 mg/m2, Etoposide 75 mg/m2, Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks)
Number of subjects: 46
Study: 25904000

Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph (MogPWV)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MogPWV
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (eGFR > 30 ml/min)
Number of subjects: 143
Study: 25904368

Group type: EXPERIMENTAL
Intervention: Acquisition of Multidrug-Resistant Enterobacteriaceae (MRE)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Acquisition of carbapenemase-producing Enterobacteriaceae
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: MRE acquisition by region
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: MRE carriage duration
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Factors associated with MRE acquisition
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Carriage duration based on region
Number of subjects: 574
Study: 25904601

Group type: EXPERIMENTAL
Intervention: 10% HFCS (n = 18)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 17.5% HFCS (n = 16)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 25% HFCS (n = 28)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 0% HFCS (aspartame sweetened, n = 23)
Number of subjects: 85
Study: 25904635

Group type: EXPERIMENTAL
Intervention: Variant rs2268361-T in FSHR
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Variant rs705702-G near RAB5B and SUOX
Number of subjects: 485
Study: 25905829

Group type: EXPERIMENTAL
Intervention: Community-based, peer-delivered stress management intervention (8-week duration)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 151
Study: 25906048

Group type: EXPERIMENTAL
Intervention: Breast conserving therapy (BCT) with surgical removal of the tumor (lumpectomy) followed by radiation treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiscale modeling to predict breast contour after BCT.
Number of subjects: 0
Study: 25906326

Group type: COMPARATOR
Intervention: Cluster I (18 COPD patients)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cluster II (45 COPD patients)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cluster III (22 COPD patients)
Number of subjects: 85
Study: 25907127

Group type: COMPARATOR
Intervention: White non-Hispanics
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Chinese Americans
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Hispanic Americans
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ethnic minority FMs
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Higher FM diabetes involvement
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Diabetes education, support success, and diabetes support network size
Number of subjects: 238
Study: 25907145

Group type: EXPERIMENTAL
Intervention: Movement training rehabilitation program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (20 asymptomatic volunteers)
Number of subjects: 25
Study: 25907171

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 80/4.5 μg one inhalation b.i.d.
Number of subjects: 4581

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg one inhalation b.i.d.
Number of subjects: 4581

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 2 x 160/4.5 μg b.i.d.
Number of subjects: 4581
Study: 25907621

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10mg/kg
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study: 25907994

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS R0)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Volume measurement
Number of subjects: 25

Group type: COMPARATOR
Intervention: Circumference measurement
Number of subjects: 25
Study: 25908064

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 882
Study: 25908158

Group type: EXPERIMENTAL
Intervention: Endogenous GLP-1 levels during liquid meal tests
Number of subjects: 0
Study: 25908235

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 4
Study: 25908674

Group type: EXPERIMENTAL
Intervention: Patients with prior stroke and heart failure
Number of subjects: 5005

Group type: COMPARATOR
Intervention: Patients without prior stroke
Number of subjects: 5005
Study: 25908679

Group type: EXPERIMENTAL
Intervention: Medication incidents identified among primary care patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 500
Study: 25908766

Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 26508

Group type: EXPERIMENTAL
Intervention: high-sensitivity C-reactive protein
Number of subjects: 26508
Study: 25908927

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids not used
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids used
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (not treated with systemic glucocorticoids)
Number of subjects: 386
Study: 25909192

Group type: EXPERIMENTAL
Intervention: 10mg of oral zinc
Number of subjects: 700
Study: 25909513

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Other atypical antipsychotics
Number of subjects: 63
Study: 25910501

Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding (GIB) after PCI
Number of subjects: 6212

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Number of subjects: 6212

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal bleeding
Number of subjects: 6212

Group type: EXPERIMENTAL
Intervention: BARC GIB events
Number of subjects: 6212
Study: 25910525

Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS)
Number of subjects: 443
Study: 25910663

Group type: EXPERIMENTAL
Intervention: Willingness to pay out-of-pocket for histopathologic polyp analysis
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to pay
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Concerns of patients unwilling to pay
Number of subjects: 500
Study: 25911223

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics for pulmonary exacerbation (PEx) treatment
Number of subjects: 123
Study: 25911554

Group type: EXPERIMENTAL
Intervention: Bendamustine plus bortezomib and prednisone (1.3 mg/m(2) bortezomib twice weekly for 6 weeks, 90 mg/m(2) bendamustine on days 1 and 4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bendamustine plus bortezomib and prednisone (for patients not candidates for transplantation)
Number of subjects: 60
Study: 25911999

Group type: EXPERIMENTAL
Intervention: 118G allele carriers
Number of subjects: 86

Group type: COMPARATOR
Intervention: 118AA homozygotes
Number of subjects: 86
Study: 25912075

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII Fc fusion protein (rFVIIIFc), starting regimen: twice-weekly prophylaxis (Day 1: 25 IU kg(-1); Day 4: 50 IU kg(-1)); adjusted dose (≤ 80 IU kg(-1)) and dosing interval (≥ 2 days) as needed.
Number of subjects: 71
Study: 25912185

Group type: EXPERIMENTAL
Intervention: Alternate Healthy Eating Index-2010 (AHEI-2010)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Prudent diet pattern
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Western diet pattern
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Meat consumption
Number of subjects: 196
Study: 25912208

Group type: COMPARATOR
Intervention: 8-valent HPV6/11/16/18/31/45/52/58 vaccine (Study 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (Study 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: qHPV vaccine plus 5-valent HPV31/33/45/52/58 (Study 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccine candidates (Studies 1, 2, and 3)
Number of subjects: 0
Study: 25912400

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 250
Study: 25913550

Group type: EXPERIMENTAL
Intervention: Etanercept, dosage and duration not available
Number of subjects: 0
Study: 25914327

Group type: EXPERIMENTAL
Intervention: 3D QCA
Number of subjects: 114

Group type: COMPARATOR
Intervention: 2D QCA
Number of subjects: 114
Study: 25914872

Group type: EXPERIMENTAL
Intervention: Web Only
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Quitline Only
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Web + Quitline
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Control (printed self-help guide)
Number of subjects: 1683
Study: 25915455

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 58